Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
35 stopped studies mapped to Uveal Melanoma and descendants · 94% state a reason
Over the 35 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT07076550 | A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408… | Phase 1 | terminated | Jul 22, 2025 | Alpha-9 Oncology USA Inc. | Due to a strategic decision to re-prioritize the sponsor's existing portfolio. | Sponsor / business decision |
| NCT05308901 | Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve… | Phase 2 | terminated | Apr 4, 2022 | Providence Health & Services | PI opted to close study due to poor accrual. | Enrollment / accrual |
| NCT03417739 | A Phase II Study of BVD-523 in Metastatic Uveal Melanoma | Phase 2 | terminated | Jan 31, 2018 | Dana-Farber Cancer Institute | This was a Simon two stage design trial that terminated after the first stage due to lack of… | Other (stated, no rule matched) |
| NCT03865212 | Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma | Phase 1 | terminated | Mar 6, 2019 | Mayo Clinic | Lack of funding; lack of objective response | Funding |
| NCT03746431 | A Phase 1 Study of [225Ac]-FPI-1434 Injection | Phase 1 | terminated | Nov 19, 2018 | Fusion Pharmaceuticals Inc. | A strategic decision was made to discontinue the study and prioritize other programs within the… | Safety / toxicity |
| NCT04935229 | Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO),… | Phase 1 | terminated | Jun 22, 2021 | TriSalus Life Sciences, Inc. | The decision was made to terminate the study after the completion of Phase 1 enrollment and not… | Safety / toxicity |
| NCT03712904 | Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal… | Phase 2 | terminated | Oct 19, 2018 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Slow accrual | Enrollment / accrual |
| NCT04720417 | Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma | Phase 2 | terminated | Jan 22, 2021 | Thomas Jefferson University | Trial enrollment was stopped early by study sponsors (before the anticipated accrual of 18… | Enrollment / accrual |
| NCT05576077 | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors(STARLING) | Phase 1 | terminated | Oct 12, 2022 | Turnstone Biologics, Corp. | Sponsor decision | Sponsor / business decision |
| NCT04879017 | FHD-286 in Subjects With Metastatic Uveal Melanoma | Phase 1 | terminated | May 10, 2021 | Foghorn Therapeutics Inc. | Sponsor terminated the study for business reasons. | Sponsor / business decision |
| NCT05482074 | Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 | Phase 2 | withdrawn | Aug 1, 2022 | Dana-Farber Cancer Institute | Principal Investigator left the institute | Investigator |
| NCT04589832 | Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma | Phase 1 / Phase 2 | terminated | Oct 19, 2020 | Arkadiusz Z. Dudek, MD | This study required dose reductions to the lower dose level (Dose level -1). But this dose level… | Funding |
| NCT02743611 | Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or… | Phase 1 / Phase 2 | terminated | Apr 19, 2016 | Bellicum Pharmaceuticals | company decision | Sponsor / business decision |
| NCT02831933 | Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung…(ENSIGN) | Phase 2 | terminated | Jul 13, 2016 | Eric Bernicker, MD | Lack of funding | Funding |
| NCT05677373 | Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in… | Phase 1 / Phase 2 | withdrawn | Jan 10, 2023 | Alliance for Clinical Trials in Oncology | The drug company supporting this trial has withdrawn support, including the ability to provide… | Sponsor / business decision |
| NCT05266430 | Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque…(IL) | — | terminated | Mar 4, 2022 | Aura Biosciences | Sponsor Decision - Low Enrollment | Enrollment / accrual |
| NCT02601378 | A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma. | Phase 1 | terminated | Nov 10, 2015 | Novartis Pharmaceuticals | The combination part of the study was terminated early due to business reasons | Sponsor / business decision |
| NCT02029690 | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With…(TRAP) | Phase 1 | terminated | Jan 8, 2014 | Polaris Group | not stated | Not stated |
| NCT01801358 | A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma | Phase 1 / Phase 2 | terminated | Feb 28, 2013 | Array Biopharma, now a wholly owned subsidiary of Pfizer | The trial was terminated for scientific reasons. | Other (stated, no rule matched) |
| NCT02336763 | Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who… | N/A | terminated | Jan 13, 2015 | Jonsson Comprehensive Cancer Center | Closed due to lack of accrual | Enrollment / accrual |
| NCT04184518 | Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma(CEDUVEAL-M) | Phase 2 | withdrawn | Dec 3, 2019 | Grupo Español Multidisciplinar de Melanoma | The Cediranib producer laboratory decided to stop the development of this product. | Other (stated, no rule matched) |
| NCT03022565 | Vorinostat in Patients With Class 2 High Risk Uveal Melanoma | Early Phase 1 | withdrawn | Jan 16, 2017 | University of Miami | Investigator Decision | Investigator |
| NCT02359851 | Pembrolizumab in Treating Patients With Advanced Uveal Melanoma | Phase 2 | terminated | Feb 10, 2015 | Vanderbilt-Ingram Cancer Center | Slow accrual | Enrollment / accrual |
| NCT01471054 | Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque… | Phase 2 | terminated | Nov 11, 2011 | Arman Mashayekhi | Could not enroll enough patients. | Enrollment / accrual |
| NCT00929019 | Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk… | Phase 1 / Phase 2 | terminated | Jun 26, 2009 | Radboud University Medical Center | slow accrual | Enrollment / accrual |
| NCT01814046 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular… | Phase 2 | terminated | Mar 19, 2013 | National Cancer Institute (NCI) | Investigator left the National Institutes of Health (NIH) | Investigator |
| NCT03326258 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced… | Phase 1 / Phase 2 | withdrawn | Oct 31, 2017 | National Cancer Institute (NCI) | The study itself was Disapproved on 04/20/2018 and will not be moving forward. | Other (stated, no rule matched) |
| NCT01533948 | Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by… | Phase 2 | terminated | Feb 16, 2012 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT01328106 | Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma | Phase 2 | withdrawn | Apr 4, 2011 | GlaxoSmithKline | The study was cancelled by the sponsor prior to initiation of study enrollment. No subjects were… | Enrollment / accrual |
| NCT00482911 | Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye… | Phase 2 | terminated | Jun 5, 2007 | National Institutes of Health Clinical Center (CC) | Investigator left the institute. | Investigator |
| NCT01730157 | Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver… | Early Phase 1 | terminated | Nov 21, 2012 | Case Comprehensive Cancer Center | Research Cancelled | Other (stated, no rule matched) |
| NCT00002947 | Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer | Phase 1 | terminated | Mar 26, 2004 | Yale University | not stated | Not stated |
| NCT00005841 | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | Phase 1 | terminated | May 26, 2004 | University of Southern California | Toxicity/Side Effects | Safety / toxicity |
| NCT00036816 | Vaccine Therapy in Treating Patients With Melanoma of the Eye | Phase 3 | terminated | Jan 27, 2003 | European Organisation for Research and Treatment of Cancer - EORTC | low accrual | Enrollment / accrual |
| NCT00110123 | Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With… | Phase 3 | terminated | May 4, 2005 | European Organisation for Research and Treatment of Cancer - EORTC | low accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Aug 31, 2026source: clinicaltrials